will encourage more data shar- ing among researchers and help inform the design of future clini- cal trials. “Once this is built, I think it’s actually going to drive the research,” he said. The PCDC team has already received philanthropic sup- port from Sammy’s Superheroes Foundation, which committed $400,000 over four years to the project (see story on pg. 29). And, they have also received funding from the Rally Foundation. “The PCDC has the promise of leveraging the success of the INRG to other pediatric cancers, accel- erating research and hopefully improving survival,” Cohn said. “As the genomic data gets more rich, additional studies will be able to be conducted that we hope will lead to a better understanding of the genomic factors that drive clin- ically aggressive tumor growth.” While they work to develop the PCDC, Volchenboum and Grossman will also lend their expertise to a new five-year, $14.8 million effort by the National Institutes of Health (contingent upon available funding) to improve the understanding of inherited diseases. The project, known as the Gabriella Miller Kids First pediat- ric data resource center, will be a multi-centered effort led by inves- tigators at the Center for Data Driven Discovery in Biomedicine at the Children’s Hospital of Philadelphia (CHOP). Teams led by Grossman and Volchenboum will design and operate the cloud-based, open- source software needed to estab- lish the data coordination center within the Kids First data resource center. Volchenboum hopes the PCDC at the University of Chicago will help provide valuable clinical data to this new genomic com- mons for pediatric cancer. Pediatric Treatment Regimens Benefit Adolescents and Young Adults Each year, about 70,000 patients aged 15–39 in the U.S. are diag- nosed with cancer, according to the National Cancer Institute, with blood cancers making up 20 per- cent of those cases. In 2012, Wendy Stock, MD, Anjuli Seth Nayak, Professor in Leukemia, and Jennifer McNeer, MD, assistant professor of pediat- rics, collaborated on the develop- ment of the Adolescent and Young Adult (AYA) Oncology Program to address the unique challenges that this population faces during treatment. “The PCDC has the promise of leveraging the success of the INRG to other pediatric cancers, accelerating research and hopefully improving survival.” — Susan Cohn, MD Dr. Jennifer McNeer with teen patient Rachael Elliott 31